The TRIUMPH-1 Phase 3 trial results are in, and the numbers are staggering: retatrutide, Eli Lilly’s triple-receptor agonist, achieved up to 30.3% average weight loss at the highest dose. That surpasses every approved weight-loss medication on the market. Here’s what it means, what the caveats are, and why the women’s health angle matters most.
Semaglutide targets one receptor (GLP-1). Tirzepatide targets two (GLP-1 + GIP). Retatrutide targets three: GLP-1, GIP, and glucagon. That third receptor — glucagon — is the key differentiator. Glucagon speeds up metabolism and helps break down fat cells for energy. This triple mechanism may explain why retatrutide’s weight loss numbers exceed both semaglutide and tirzepatide.
In a large-scale review published in Annals of Internal Medicine evaluating 12 GLP-1 receptor agonists across 26 randomized controlled trials with 15,491 adults, retatrutide had already established itself as the top-performing investigational agent, leading the field with an anticipated 24.2% weight loss at 12mg weekly — outpacing tirzepatide’s maximum of 17.8% and semaglutide’s 13.9%.
The TRIUMPH-1 Phase 3 results now exceed even those Phase 2 projections.
While retatrutide was generally tolerable, 11.3% of participants at the highest dose discontinued due to adverse events, compared to 4.9% in the placebo group. Some analysts suggest this tolerability profile could confine the drug to patients at the higher end of the BMI spectrum, while tirzepatide continues as the first-line option for broader populations.
A critical question the industry is watching: does retatrutide preserve lean body mass and bone mineral density? Perimenopausal and menopausal women already face natural declines in both. A 2025 RAND analysis noted that women aged 50-64 have the highest GLP-1 use overall, but these same women are most vulnerable to muscle and bone loss from aggressive weight loss. Lilly plans to present more detailed data at the 2026 ADA congress.
Retatrutide cannot be prescribed outside of a clinical trial. A head-to-head trial directly comparing retatrutide to tirzepatide is expected to finish in December 2026. The earliest realistic FDA approval would be sometime in 2027.
The most interesting signal for women may not come from retatrutide alone, but from its potential combination with hormone therapy. A 2024 Mayo Clinic retrospective study found that postmenopausal women using tirzepatide plus HRT lost approximately 30-35% more weight than women on tirzepatide alone. If this synergy extends to retatrutide (and the mechanistic rationale suggests it should), the combination could be transformative for menopausal weight management.
A separate study in Metabolic Syndrome and Related Disorders found that postmenopausal women on low-dose semaglutide (1mg) lost comparable weight to premenopausal women after four months, despite starting with higher fat mass — suggesting these drugs work well across the menopausal transition when properly dosed.
| Drug | Receptors | Max Weight Loss | Status |
|---|---|---|---|
| Semaglutide (Wegovy/Ozempic) | GLP-1 | ~14% | FDA Approved |
| Tirzepatide (Zepbound/Mounjaro) | GLP-1 + GIP | ~21% | FDA Approved |
| Retatrutide | GLP-1 + GIP + Glucagon | ~30% | Phase 3 (TRIUMPH) |
Retatrutide is still in Phase 3 clinical trials conducted by Eli Lilly. A head-to-head trial comparing retatrutide to tirzepatide is expected to finish in December 2026. The earliest realistic FDA approval would be sometime in 2027. It cannot be legally prescribed outside of a clinical trial right now.
Early data suggests potentially greater weight loss: up to 30.3% with retatrutide vs. approximately 21% with tirzepatide and 14% with semaglutide. However, head-to-head Phase 3 comparisons are still ongoing. Retatrutide also had higher discontinuation rates due to side effects (11.3% at the highest dose vs. 4.9% for placebo), which could limit its use.
No direct data exists for menopausal women specifically. However, the HRT + GLP-1 synergy observed with tirzepatide (30-35% more weight loss when combined with hormone therapy) may also apply to retatrutide. Retatrutide's additional glucagon receptor activity, which speeds metabolism and breaks down fat cells, could be particularly relevant for menopause-associated visceral fat accumulation.
Retatrutide is not available through compounding pharmacies. Some research peptide vendors sell it, but these products are sold as research chemicals and are not intended for human use. The only legal way to access retatrutide is through enrollment in a clinical trial.